Compare AZIO & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZIO | HBIO |
|---|---|---|
| Founded | N/A | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 26.5M |
| IPO Year | 2014 | 2000 |
| Metric | AZIO | HBIO |
|---|---|---|
| Price | $1.58 | $6.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 268.6K | 12.9K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,939,008.00 | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 217.58 | N/A |
| 52 Week Low | $1.23 | $0.38 |
| 52 Week High | $1.84 | $7.50 |
| Indicator | AZIO | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 60.08 |
| Support Level | $1.32 | $5.91 |
| Resistance Level | $1.76 | $6.78 |
| Average True Range (ATR) | 0.20 | 0.30 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 62.23 | 88.31 |
Azio AI Holdings Inc is a technology infrastructure company focused on developing, owning, and operating artificial intelligence data centers, enterprise GPU compute infrastructure, digital power solutions, and digital asset mining operations. The company operates an integrated AI infrastructure business encompassing AI data center development, the sale and distribution of enterprise GPU systems and server infrastructure, high-performance computing solutions, power hosting, and strategic technology investments, serving enterprise and institutional customers across domestic and international markets.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.